Chronic treatment with naltrexone enhances morphine-stimulated dopamine neurotransmission: neurochemical and behavioral evidence. Neuropharmacology, 27(11), 1103-9. https://doi.org/10.1016/0028-3908(88)90004-4
. (1988). JL Neisewander
First name:
JL
Last name:
Neisewander
Phenylpiperazine derivatives with selectivity for dopamine D3 receptors modulate cocaine self-administration in rats. Neuropharmacology, 63(8), 1346-59. https://doi.org/10.1016/j.neuropharm.2012.08.011
. (2012). Fos expression in response to dopamine D3-preferring phenylpiperazine drugs given with and without cocaine. Synapse (New York, N.y.), 67(12), 847-55. https://doi.org/10.1002/syn.21691
. (2013). Individual differences and social influences on the neurobehavioral pharmacology of abused drugs. Pharmacological Reviews, 65(1), 255-90. https://doi.org/10.1124/pr.111.005124
. (2013). Conditioned place preference with morphine: the effect of extinction training on the reinforcing CR. Pharmacology, Biochemistry, And Behavior, 21(4), 545-9. https://doi.org/10.1016/s0091-3057(84)80037-4
. (1984). Repeated testing attenuates conditioned place preference with cocaine. Psychopharmacology, 89(2), 239-43. https://doi.org/10.1007/BF00310636 (Original work published 1986)
. Single-trial conditioned place preference using intravenous morphine. Pharmacology, Biochemistry, And Behavior, 25(5), 1101-5. https://doi.org/10.1016/0091-3057(86)90092-4
. (1986). Expression of morphine-conditioned hyperactivity is attenuated by naloxone and pimozide. Psychopharmacology, 93(3), 314-9. https://doi.org/10.1007/BF00187249 (Original work published 1987)
. Chronic naltrexone supersensitizes the reinforcing and locomotor-activating effects of morphine. Pharmacology, Biochemistry, And Behavior, 28(2), 267-73. https://doi.org/10.1016/0091-3057(87)90224-3
. (1987). Impaired supersensitivity to morphine following chronic naltrexone treatment in senescent rats. Neurobiology Of Aging, 15(1), 91-7. https://doi.org/10.1016/0197-4580(94)90148-1 (Original work published 1969)
. (1969).